Ganesan Vaidyanathan
Overview
Explore the profile of Ganesan Vaidyanathan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
1185
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huynh T, Feng Y, Meshaw R, Zhao X, Rosenfeld L, Vaidyanathan G, et al.
Nucl Med Biol
. 2024 May;
134-135:108913.
PMID: 38703588
Introduction: Single domain antibody fragments (sdAbs) are an appealing scaffold for radiopharmaceutical development due to their small size (~15 kDa), high solubility, high stability, and excellent tumor penetration. Previously, we...
2.
Feng Y, Meshaw R, Finch S, Zheng Y, Minn I, Vaidyanathan G, et al.
Nucl Med Biol
. 2024 May;
134-135:108916.
PMID: 38703587
Introduction: Targeted α-particle therapy agents have shown promising responses in patients who have developed resistance to β-particle emitting radionuclides, albeit off-target toxicity remains a concern. Astatine-211 emits only one α-particle...
3.
Feng Y, Sarrett S, Meshaw R, Vaidyanathan G, Cornejo M, Zeglis B, et al.
J Med Chem
. 2022 Nov;
65(22):15358-15373.
PMID: 36368007
Because of their rapid tumor accumulation and normal tissue clearance, single-domain antibody fragments (sdAbs) are an attractive vehicle for developing radiotherapeutics labeled with the α-emitter At. Herein, we have evaluated...
4.
Procissi D, Jannetti S, Zannikou M, Zhou Z, McDougald D, Kanojia D, et al.
Neurooncol Adv
. 2022 Sep;
4(1):vdac135.
PMID: 36128586
Background: Single-domain antibody fragments (aka VH, ~ 13 kDa) are promising delivery systems for brain tumor theranostics; however, achieving efficient delivery of VH to intracranial lesions remains challenging due to...
5.
Batra V, Samanta M, Makvandi M, Groff D, Martorano P, Elias J, et al.
Clin Cancer Res
. 2022 Jul;
28(18):4146-4157.
PMID: 35861867
Purpose: [131I]meta-iodobenzylguanidine ([131I]MIBG) is a targeted radiotherapeutic administered systemically to deliver beta particle radiation in neuroblastoma. However, relapses in the bone marrow are common. [211At]meta-astatobenzylguanidine ([211At] MABG) is an alpha...
6.
Feng Y, Meshaw R, Zhao X, Jannetti S, Vaidyanathan G, Zalutsky M
J Nucl Med
. 2022 May;
64(1):124-130.
PMID: 35618478
Single-domain antibody fragments (sdAbs) are attractive for targeted α-particle therapy, particularly with At, because of their rapid accumulation in tumor and clearance from normal tissues. Here, we evaluate the therapeutic...
7.
Feng Y, Meshaw R, McDougald D, Zhou Z, Zhao X, Jannetti S, et al.
Sci Rep
. 2022 Feb;
12(1):3020.
PMID: 35194100
Radiopharmaceutical therapy (RPT) is an attractive strategy for treatment of disseminated cancers including those overexpressing the HER2 receptor including breast, ovarian and gastroesophageal carcinomas. Single-domain antibody fragments (sdAbs) exemplified by...
8.
Liu Y, Zhou Z, Feng Y, Zhao X, Vaidyanathan G, Zalutsky M, et al.
Int J Nanomedicine
. 2021 Nov;
16:7297-7305.
PMID: 34737567
Aim: To develop an innovative At nanoplatform with high radiolabeling efficiency and low in vivo deastatination for future targeted alpha-particle therapy (TAT) to treat cancer. Methods: Star-shaped gold nanoparticles, gold...
9.
Zhou Z, McDougald D, Meshaw R, Balyasnikova I, Zalutsky M, Vaidyanathan G
Nucl Med Biol
. 2021 Jun;
100-101:24-35.
PMID: 34146837
Introduction: Labeling single domain antibody fragments (sdAbs) with F is an attractive strategy for immunoPET. Earlier, we developed a residualizing label, N-succinimidyl 3-((4-(4-fluorobutyl)-1H-1,2,3-triazol-1-yl)methyl)-5-(guanidinomethyl)benzoate ([F]RL-I), synthesized via a click reaction for...
10.
Mease R, Kang C, Kumar V, Banerjee S, Minn I, Brummet M, et al.
J Nucl Med
. 2021 Jun;
63(2):259-267.
PMID: 34088772
α-Particle emitters targeting the prostate-specific membrane antigen (PSMA) proved effective in treating patients with prostate cancer who were unresponsive to the corresponding β-particle therapy. At is an α-emitter that may...